Towards Enzyme-like, Sustainable Catalysis: Switchable, Highly Efficient Asymmetric Synthesis of Enantiopure Biginelli Dihydropyrimidinones or Hexahydropyrimidinones
作者:V. J. Lillo、J. M. Saá
DOI:10.1002/chem.201604433
日期:2016.11.21
Organocatalysts displaying a network of cooperative hydrogen bonds (NCHB) have been employed in an enzyme‐like manner for a direct, switchable synthesis of enantiopure hexahydropyrimidinones (HHPMs) or dihydropyrimidinones (DHPMs), which starts at a common, easily accessible α‐ureidosulfone stage. The NCHB organocatalyst exploits all its potential as a pure hydrogen‐bond biomimetic catalyst even in
Enantioselective Synthesis of SNAP-7941: Chiral Dihydropyrimidone Inhibitor of MCH1-R
作者:Jennifer M. Goss、Scott E. Schaus
DOI:10.1021/jo801463j
日期:2008.10.3
alkaloid-catalyzed Mannich reaction of beta-keto esters to acylimines and the second was the chiral phosphoric acid-catalyzed Biginelli reaction. Completion of the synthesis was accomplished via selective urea formation at the N3 position of the dihydropyrimidone with the 3-(4-phenylpiperidin-1-yl)propylamine side chain fragment. The synthesis of SNAP-7921 highlights the utility of asymmetric organocatalytic
ENANTIOSELECTIVE SYNTHESIS OF DIHYDROPYRIMIDINONES AND HEXAHYDROPYRIMIDINONES
申请人:Universitat de les Illes Balears
公开号:EP3260446A1
公开(公告)日:2017-12-27
The present invention provides with a "one pot" easily scalable preparation process, or method to obtain enantiomerically enriched dihydropyrimidinones (DHPMs), in high yield and high enantiomeric purity, based on the concept of organocatalysis by a network of cooperative hydrogen bonds (NCHB). Said preparation process obtains enantiomerically enriched DHPMs without the use of metal-based catalysis and with the possibility of the recovery of the chiral organocatalyst comprising a NCHB used. The present invention also provides with new enantiomerically and diastereomerically enriched hexahydropyrimidinones (HHPMs), as well as a preparation process to obtain them also based on the concept of organocatalysis by a NCHB. Said preparation process obtains enantiomerically and diastereomerically enriched HHPMs without the use of metal-based catalysis and with the possibility of the recovery of the chiral organocatalyst comprising a NCHB used.
In Vitro and in Vivo Evaluation of Dihydropyrimidinone C-5 Amides as Potent and Selective α<sub>1A</sub> Receptor Antagonists for the Treatment of Benign Prostatic Hyperplasia
作者:James C. Barrow、Philippe G. Nantermet、Harold G. Selnick、Kristen L. Glass、Kenneth E. Rittle、Kevin F. Gilbert、Thomas G. Steele、Carl F. Homnick、Roger M. Freidinger、Rick W. Ransom、Paul Kling、Duane Reiss、Theodore P. Broten、Terry W. Schorn、Raymond S. L. Chang、Stacey S. O'Malley、Timothy V. Olah、Joan D. Ellis、Andrea Barrish、Kelem Kassahun、Paula Leppert、Dhanapalan Nagarathnam、Carlos Forray
DOI:10.1021/jm990612y
日期:2000.7.1
alpha(1) Adrenergic receptors mediate both vascular and lower urinary tract tone, and alpha(1) receptor antagonists such as terazosin (1b) are used to treat both hypertension and benign prostatic hyperplasia (BPH). Recently, three different subtypes of this receptor have been identified, with the alpha(1A) receptor being most prevalent in lower urinary tract tissue. This paper explores 4-aryldihydropyrimidinones attached to an aminopropyl-4-arylpiperidine via a C-5 amide as selective alpha(1A) receptor subtype antagonists. In receptor binding assays, these types of compounds generally display K-i values for the alpha(1a) receptor subtype <1 nM while being greater than 100-fold selective versus the alpha(1b) and alpha(1d) receptor subtypes. Many of these compounds were also evaluated in vivo and found to be more potent than terazosin in both a rat model of prostate tone and a dog model of intra-urethral pressure without significantly affecting blood pressure. While many of the compounds tested displayed poor pharmacokinetics, compound 48 was found to have adequate bioavailability (>20%) and half-life (>6 h) in both rats and dogs. Due to its selectivity for the alpha(1a) over the alpha(1d) and alpha(1d) receptors as well as its favorable pharmacokinetic profile, 48 has the potential to relieve the symptoms of BPH without eliciting effects on the cardiovascular system.
Highly Enantioselective Organocatalytic Biginelli and Biginelli-Like Condensations: Reversal of the Stereochemistry by Tuning the 3,3′-Disubstituents of Phosphoric Acids
作者:Nan Li、Xiao-Hua Chen、Jin Song、Shi-Wei Luo、Wu Fan、Liu-Zhu Gong
DOI:10.1021/ja905320q
日期:2009.10.28
and Biginelli-likereactions by chiral phosphoric acids derived from 3,3'-disubstituted binaphthols have been investigated. The size of 3,3'-substituents of the catalysts is able to control the stereochemistry of the Biginelli reaction. By tuning the 3,3'-disubstituents of the phosphoric acids, the stereochemistry of the Biginelli reaction can be reversed. This organocatalytic Biginelli reaction by